Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Synaptogenix ( (SNPX) ) is now available.
Synaptogenix has extended the employment term of its CEO, Dr. Alan J. Tuchman, with a reduced salary and entered a new consulting agreement with its President, Dr. Daniel L. Alkon, also with a reduced fee. The company is focusing on strategic opportunities to enhance investor value, supported by $19.6 million in cash reserves. Synaptogenix is exploring partnerships and non-dilutive investments for its Bryostatin-1 asset, while also reducing its cash burn rate by terminating a Phase 1 trial due to slow enrollment.
More about Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. Its lead therapeutic candidate, Bryostatin-1, has been studied in Alzheimer’s disease and other conditions such as Fragile X syndrome and multiple sclerosis. The company benefits from Orphan Drug Designation for Bryostatin-1 in treating Fragile X syndrome.
YTD Price Performance: -62.28%
Average Trading Volume: 20,633
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.48M
For detailed information about SNPX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue